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Abstract
Background: Little is known about the applicability of dual treatments based on integrase inhibitors. We explored
the combination of lamivudine + dolutegravir as an option when switching from standard cART in virologically
suppressed patients.
Methods: In this prospective cohort we enrolled patients previously switched to 3TC + DTG who were 18 years or
older, with no previous resistance mutations to the used drugs, having a HIV-RNA <50 copies/ml for 6 months or
longer, negative for HBsAg and on a stable (>6 months) cART.
Results: Ninety-four individuals were included. They were mostly men (77.7%) with a mean age of 53 years. They
presented 159 co-morbidities including cardiovascular, bone, hepatic, kidney, and CNS diseases. Because of these
pathologies, they took 207 non-ARV drugs (mean 2.2 per patient). Median duration of viral suppression was 77.
5 months (IQR 61). All subjects were prospectively followed up to week 24 and all remained on dual therapy during
the whole period. Neither virological failure, nor viral blip was detected.
The median CD4 count rose from 658 cells/mcl (IQR 403) to 724 cells/mcl (IQR 401) (P = 0.006) without a significant
(P = 0.44) change in the CD4/CD8 ratio. A significant (P < 0.0001) increment of median creatinine from 0.87 mg/dl
(IQR 0.34) to 0.95 mg/dl (IQR 0.29) was observed in the first 2 months but thereafter leveled on these values
(1.00 mg/dl; IQR 0.35) (P = 0.111 compared to 2 months). The lipid profile slightly improved. The daily cost of cART
was significantly (P < 0.0001) reduced of 6.89 euros (SD 6.10).
Discussion: Switching to a dual cART regimen based on lamivudine + dolutegravir maintains virological efficacy up to
week 24, and is associated to slight improvements of the immunologic and metabolic status. The strategy allows to
freely using concomitant medications for associated pathologies. The dual therapy is less expensive in economic terms.
Conclusion: Although still limited evidence exists, a dolutegravir-based dual therapy in combination with lamivudine
shows promising results to be confirmed in larger controlled trials.
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Background
In the first years of HIV epidemic the sequential use of
nucleoside reverse transcriptase inhibitors (NRTI) as
monotherapy or dual therapies rapidly led to treatment
failure because of the emergence of resistance-associated
mutations [1]. Later, the use of combination antiretro-
viral therapy (cART), in which two NRTIs were com-
bined with a third agent from a different therapeutic
class, became the standard of care. Current treatment
guidelines continue the convention of preferred cART
based on combining a dual NRTI backbone with a third
“anchor” agent [2, 3] as initial treatment. With the im-
proved potency and tolerability and the higher barrier to
the development of resistance of newer drugs interest
has re-emerged for ARV-sparing strategies including
monotherapy and dual therapies. A reduced drug burden
could be of interest as patients with HIV are now living
longer with an increasing prevalence of comorbidities
associated with natural aging, including renal, cardiovas-
cular, or liver diseases; cognitive decline; metabolic
disorders such as diabetes and dyslipidemia; and osteo-
porosis [4]. Drug-related adverse events (AEs) associated
with the long-term use of cART may contribute to these
comorbidities [5–11].
Dual regimens have been applied as initial therapy in
ARV-naive patients or as a switch strategy in those
patients who have become virologically suppressed on
standard regimens [12–17]. Ideally, these regimens
should achieve and maintain viral suppression and
immunologic control while minimizing short- and long-
term AEs, improve adherence and convenience, and
reduce drug-drug interactions and costs. The Italian
Guidelines for the treatment of HIV-infected adults [18]
contain an entire chapter on “optimization” of cART
with less-drug-regimens (LDR). It is recognized that
reasons leading to the choice of a LDR (dual or mono
therapies) include: a) intolerance to the ongoing regi-
men; b) presence of co-morbidities on which the current
regimen could be detrimental: c) prevention of long-term
toxicity; d) current regimen not anymore recommended;
e) drug-drug interactions; and f) need to improve treat-
ment adherence.
Little is known about the applicability of dual treat-
ments based on integrase inhibitors and a NRTI. We
report a prospective, clinical, uncontrolled experience on
patients switched, while virologically suppressed, to the
combination of dolutegravir plus lamivudine that is
considered by Italian Guidelines as optional (CII) [18].
Methods
We considered for inclusion in this cohort only patients
that, at the moment of therapeutic switch, had a HIV-
RNA <50 copies/ml for 6 months or longer. All were
negative for hepatitis B virus surface antigen, and were
on a stable (>6 months) cART generally based on a
nucleosidic backbone plus a third anchor agent, or, in a
few cases on other complex regimens. Further, only pa-
tients with no previous resistance mutations to either
integrase inhibitors or lamivudine were selected. Resist-
ance had to be determined by genotypic analysis before
the start of cART or afterward in the occasion of viral
blips before the current regimen was started. Patients
were not included if they had a viral failure following
their last genotypic test.
No experimental procedure (e.g. randomization) was
applied, and drugs were used according to a considered
alternative option in Italian Guidelines. In all patients,
the decision to switch therapy was taken on clinical
grounds as they presented a clinically relevant reason,
either because of concomitant diseases, altered labora-
tory tests, drug adverse events or risk of drug-to-drug
interactions. The drug combination was presented as a
possible alternative and discussed individually according
to clinical needs. The possibility to use the dual combin-
ation was discussed according to available data [40] and
to results obtained with similar dual therapies [15, 16].
Alternatives were presented according to the specific
clinical situation and comprehended (but were not
limited to): a) possible alternative regimens such as for
example 3TC + ATV/r or more complex combinations
(either with 2 or 3 active agents e.g. INI + PI +MRV or
INI + NNRTI + PI); b) the possibility to add therapies to
counter-act specific adverse events (e.g. alendronate for
osteoporosis or statins for dyslipidemia) with the pos-
sible connected adverse events (to stay with the previous
example, gastro-intestinal discomfort; myalgia or myop-
athy); c) the possibility to increase the frequency of
clinical controls to closely monitor clinical alterations
(e.g. renal insufficiency); d) the possibility to overcome
current adverse events by accepting different potential
risks (e.g. stopping TDF for osteoporosis and starting
ABC with potential CV risk); e) the possibility to change
indicated adjunctive therapies because of risk of drug in-
teractions (e.g. PPIs, Flumetasone, statins, amiodarone);
f ) the possibility to postpone needed but not life-saving
treatments (e.g. DAAs for chronic HCV infection). The
choice of the dual regimen was therefore a part of the
patient/doctor relationship during normal clinical prac-
tice. Although patients were followed prospectively,
none of them switched therapy after the decision to per-
form this analysis, consequently the local EC ruled out
that no formal ethics approval was required and patients
gave their informed consent solely for the use of clinical
and laboratory data.
All patients were switched to a dual combination of
dolutegravir (50 mg once daily) plus lamivudine (300 mg
once daily). The switch was independent from the deci-
sion to include the patients in this cohort. Once included,
Maggiolo et al. BMC Infectious Diseases  (2017) 17:215 Page 2 of 7
the patients were followed prospectively for at least six
months
Patients were followed accordingly to current clinical
practice as indicated from Italian guidelines with visits
after 2, 4, 6 month and thereafter every 3–4 months.
Each visit included a physical examination and blood
and urine analysis performed using standard methods.
For the only seek of this analysis, the primary endpoint
was the virological response, defined as the proportion
of patients with HIV viral load below 50 copies per milli-
liter 24 weeks after the switch.
Several other commonly collected data were used to
evaluate possible secondary endpoints. We analyzed
safety and tolerability by questioning patients at each
visit and by physical examination and laboratory ana-
lysis. We evaluated immunological changes in terms of
classical CD4+, CD8+ cell/counts variation and we also
collected changes in creatinine and blood lipid content
as possible markers of drug toxicity.
Data are presented as medians and interquartile range
or percentages. Student’s t-test for paired samples was
employed to identify significant changes in immuno-
logical, renal and metabolic functions. We did all statis-
tical analyses using SPSS version 17.
Results
Ninety-four individuals switched their regimen. All of
them remained on lamivudine + dolutegravir dual ther-
apy for the whole 24 weeks period. Patients continued
the dual therapy thereafter and the median follow-up of
the cohort was of 17.4 months (IQR 6.6) for 128.5 pa-
tient/years at the moment this report was written
Patients were mostly men of middle age and of Italian
origin. Baseline characteristics are summarized in Table 1.
The patients had a long cART history and were on
average on their fourth line of therapy. Most of patients
(93.6%) were, at baseline, taking a triple-drug regimen,
being the most common backbones tenofovir + emtrici-
tabine (52.1%) or abacavir + lamivudine (36.2%). The
most common anchor drugs were efavirenz (28.3%) and
nevirapine (13.8%) among NNRTIs and either boosted
atazanavir (13.8%) or boosted darunavir (12.8%) among
PIs. A previous exposure to INI was documented in
14.9% of individuals. Only 6 subjects were on a dual
therapy maraviroc + boosted darunavir (2); raltegravir +
boosted darunavir (2); etravirine + boosted darunavir and
etravirine + raltegravir (1 each).
The main reasons for therapeutic switch were concomi-
tant diseases and abnormality of laboratory tests followed
by drug related adverse events or possible adverse events or
a potential drug-drug interaction. A mix of reasons was
present in a remaining minority of patients (Table 1). Over-
all, they presented 159 co-morbidities (Fig. 1). Because of
these pathologies, the patients took 207 different drugs
(mean 2.2; SD 1.7 drugs per patient) including, but not
limited to, diuretics, beta-blockers, Ca-antagonists, ASA,
statins, benzodiazepines, vitamins, PPI, insulin, metformin.
At baseline all patients had a viral load < 50 copies/ml. The
same HIV-RNA level was detected in all patients after 2
and 6 months from the switch. Neither virological failure,
Table 1 Baseline characteristics of the 94 patients
Characteristic Median or percentage IQR
Gender (masculine) 77.7%
Age (years) 52 13
Risk factor for HIV
Heterosexual contacts 54.3%
Homosexual contacts 23.4%
Intravenous drug use 20.2%
Other 2.1%
Number of ARV drug lines 3 4
Time on cART (years) 10 12
Time on current cART (months) 37.5 61
Time below detection limit for
HIV (months)
77.5 61
Drugs in baseline ARV regimen
(patients treated with drug)
TDF 52.1%
ABC 36.2%
AZT 3.2%
EFV 28.7%
NVP 13.8%
RPV 10.6%
ETR 4.3%
ATV/r 13.8%
DRV/r 12.8%
APV/r 1.1%
LPV/r 1.1%
RAL 9.6%
DTG 5.3%
EVG 2.1%
CD4 (cells/mcL) 673 403
Reasons for drug switch
Concomitant disease 30.9%
Abnormal laboratory test 28.7%
Adverse Events 19.1%
Drug/drug interaction 13.8%
Concomitant diseases + abnormal
laboratory test
4.3%
Adverse events + drug/drug interaction 2.1%
Abnormal laboratory test + drug/drug
interaction
1.1%
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nor viral blip above 50 copies/ml was detected. The median
baseline CD4 count was 673 cells/mcl (IQR 403), at six
months it raised to 724 cells/mcl (IQR) (P = 0.006) without
a significant (P = 0.44) change in the CD4/CD8 ratio that
varied from 0.83 (IQR 0.75) to 0.95 (IQR 0.77). A significant
(P < 0.0001) increment of mean creatinine, 0.06 mg/dl in
magnitude, was observed in the first two months raising
the baseline value of 0.87 mg/dl (IQR 0.34) to 0.95 mg/dl
(IQR 0.29), but thereafter leveled on these values being the
median after 6 months 1.00 mg/dl (IQR 0.35) (P = 0.111
compared to 2 months). The lipid profile slightly changed
after switching to the dual regimen: total cholesterol
−7 mg/dl (p = 0.047); LDL-cholesterol −7 mg/dl (P = 0.355);
HDL-cholesterol +4 mg/dl (P = 0.036) and triglycerides
−31 mg/dl (P = 0.012); although differences were dependent
on pre-switch type of cART, too (Fig. 2).
During the 6 month follow-up 3 patients were admit-
ted to hospital because of causes judged unrelated to
cART: diabetes, sub-dural hematoma and coronary stent
positioning (one each).
At the end of follow-up (median 17.4 months) all
patients still receiving the same ARV therapy (91/94)
had a viral load was < 50 copies/ml and their median
CD4 count was 763 cells/mcl (IQR 491) (P = 0.002 vs
baseline). One patient was lost to follow-up and two
patients died between the sixth month of therapy and
the end of follow-up because of variceal bleeding due
to an alcoholic cirrhosis and because of pulmonary
cancer with brain metastasis (one case each). Finally,
by changing regimen, the daily cost of cART was
significantly (P < 0.0001) reduced of 6.89 euros (SD
6.10 euros) (Additional file 1).
Fig. 1 Concomitant diseases in the 94 patients
Fig. 2 Lipid variation. Difference in blood concentrations between baseline and 6 months
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Discussion
Toxicities associated with antiretroviral agents are often
drug class specific. Hyperlipidemia has been commonly as-
sociated with protease inhibitor (PI) use [19, 20], whereas
mitochondrial toxicity (lipoathrophy, functional kidney
dysfunction, cardiovascular accidents, and osteoporosis)
[21, 22] has been associated with nucleoside analogs use.
To overcome this situation, different strategies considering
PI/rtv-based dual regimens have been proposed. Most of
them addressed the association of raltegravir [12, 13, 23];
lamivudine [14–16]; a non-nucleoside inhibitors (NNRTI)
[17, 24] or maraviroc [25] to the boosted PI.
So far, however, the need of maintaining the efficacy and
convenience of robust cART forced clinicians to include a
boosted-PI in dual-therapy regimens. Consequently, the
potential benefits for some organ systems (e.g., kidney,
cardiovascular disease, and bone) were balanced by poten-
tial detriments in others (e.g., hyperlipemia).
The integrase inhibitor (INI) class has been increas-
ingly recognized as a first-line option, especially because
of its good efficacy and tolerability [2, 3].
In combination with two NRTI, the INI class was found
to be superior to boosted-PIs [26, 27] or efavirenz [28–30]
in large controlled studies, even though raltegravir showed
a lower genetic barrier compared to dolutegravir [26].
In fact, dolutegravir is not only as efficient as raltegravir
as a first-line strategy, but, similarly to boosted-darunavir, it
is characterized by a high affinity to its target, resulting in
strong and sustained binding [29]. Therefore, in vitro selec-
tion of mutants resistant to dolutegravir is very difficult.
To date, no emergent dolutegravir-resistant virus has
ever been reported in a patient in whom dolutegravir was
prescribed as a first therapy [31]. Nevertheless, patients in
whom a first-generation INI has failed may have selected
a pathway leading to cross-resistance, including dolutegra-
vir [32]. As a matter of fact, a few recent communications
have explored the possibility of dolutegravir monotherapy
[33–36] and two of them reported 4 patients out of 61
(6.6%) who failed while on dolutegravir as monotherapy:
all of them had been exposed to a first-generation INI (i.e.
raltegravir or elvitegravir) [33, 34]. Better results have been
obtained in some studies exploring the switch to a dual
therapy using dolutegravir either in combination with
rilpivirine [36, 37] or lamivudine [36, 38, 39], the latest
being explored in naïve patients, too [40, 41]. Although
small in numbers and heterogeneous in nature, these
experiences have documented a substantial virological
efficacy and tolerability of the dual regimens without
exposing patients to the risk of selecting for INSTI-
inducing resistance mutations.
To our knowledge, we report the largest cohort of pa-
tients simplified to the dual 3TC + dolutegravir regimen.
The studied cART was effective in maintaining HIV-
RNA suppression in a cohort of treatment-experienced
participants. We did not observe any virological failure,
or any viral blip over the 50 copies/ml threshold. The
switch therapy offered hints of an improved immuno-
logical outcome even in patients who already immune-
reconstituted. The reduction of mitochondrial toxicity
due to the reduced utilization of NRTIs may possibly ex-
plain this result [42]. Therapy was well tolerated and no
patients stopped therapy because of low tolerability of
dolutegravir. This is in contrast with the results recently
described by a Dutch group [43] suggesting a high propor-
tion of psychiatric adverse events leading to dolutegravir
discontinuation, despite the fact that our population, al-
though numerically smaller, was wide enough to detect a
problem of that size. Being all our patients treatment-
experienced may have affected their perception of the
overall tolerability of the regimen. Alternatively, the use of
a reduced number of active drugs and/or the limitation of
NRTI use may improve treatment acceptance. In our
study, the dual combination resulted clinically neutral on
the renal function and the creatinine increment we
observed, although statistically significant, was of limited
entity, occurred soon after the switch and stabilized there-
after. These changes are consistent with dolutegravir
action as an inhibitor of the renal protein organic cation
transporter 2 (OCT2) [44, 45].
As far as the lipid profile is concerned, our results are
substantially similar to previously reported findings using
the same drug combination [39]. We observed a reduction
of triglycerides and total cholesterol, an increment of
HDL-cholesterol, and stable levels of LDL-cholesterol;
however, the pre-switch therapies influencing the baseline
lipidic asset may influence the post-switch variation entity.
With this respect, the use of triple drug combinations in-
cluding boosted-PIs or backbones including abacavir may
explain differences with previous experiences [36, 39].
Along with treatment-emergent toxicities, concomi-
tant pathologies and the potential interactions with
drugs used to treat these diseases were among the most
frequent reasons for switching to the dual drug regimen.
With this respect the combination of lamivudine and
dolutegravir was safe and did not limit therapeutic
choices (e.g. statins, GI-tract drugs, etc.). Finally, being
the generic form of lamivudine available, the dual com-
bination was economically convenient compared to all
preferred regimens [2, 3].
Clearly, this observational study has several limita-
tions: first of all, its nature does not allow for compari-
son with a control group, although we tried to limit
analysis bias with the prospective design; second, the
limited (in number) inclusion criteria allowed for a ra-
ther heterogeneous population (i.e.: wide CD4+ T-cell
range, reasons for switching, associated drugs). We tried
to limit this confounding bias by enrolling into the co-
hort only patients with a known therapeutic history and
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a controlled HIV viremia. Finally, besides maintenance
of virological suppression, we analyzed only a small
group of safety parameters and considered as relevant
only adverse events leading to treatment discontinu-
ation. This may be a limit in a research setting, but
strictly reflects a clinical relevance.
Conclusion
In conclusion, we demonstrated in an uncontrolled co-
hort of pre-treated individuals that switching to a dual
cART regimen based on the association of lamivudine
and dolutegravir is virologically effective up to 24 weeks,
and is associated to slight improvements of the immuno-
logic and metabolic status. This regimen should still be
considered as under-investigated and its use cannot be
considered routinely. However, the strategy, compared
to several alternative ARV regimens, allows to reduce
the risk of drug-drug interactions and to use safely con-
comitant medications for associated pathologies. The
dual therapy, at least in our economic environment, is
less expensive than most alternative ARV regimens, too.
In the near future, with the availability of new nucleotidic
molecules [44] the clinical concern about some of the vari-
ables that lead to the therapeutic switch (NRTI-related tox-
icities) could become less compelling, however, having
therapeutic alternatives is always to be considered ad-
vantageous as can allow to personalize therapy in indi-
vidual patients. Although still limited evidence exists, a
dolutegravir-based dual therapy in combination with
lamivudine shows promising results to be confirmed in
larger controlled trials.
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